Substitute for fo	rm 1449A/PTO			Complete if Known			
		~~	1 pag pag	Application Number	10/544,146		
	ATION DISCL			Filing Date May 5, 2006			
STATEMENT BY APPLICANT				First Named Inventor Shyam S. Mohapatra			
(use as many sheets as necessary)				Art Unit 1635			
				Examiner Name	Richard A. Schnizer		
Sheet	1	of	2	Attorney Docket Number	USF.T193XC1		

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. 1	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	U1	US-2004/0259247 A1	12-23-2004	Tuschl <i>et al</i> .	All		
	U2	US-2005/0106598 A1	05-19-2005	Manoharan et al.	All		
	U3	US-6,391,318	05-21-2002	Illum et al.	All		
	U4	US-7,297,786	11-20-2007	McCray <i>et al.</i>	All		
	U5						
	U6						
	U7						
	U8						
	U9						

FOREIGN PATENT DOCUMENTS						
		Foreign Patent Document	Dublication Data	Name of Florida	Pages, Columns, Lines,	
Examiner Initials*	Cite No. <sup>1</sup>	Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	$T^6$
	F1					
	F2					
	F3					
	F4					
	F5					
	F6					

_			
	miner	 Date	
Signa	ature	Considered	J

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kind Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449B/PTO

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

2 2

Complete if Known				
Application Number	10/544,146			
Filing Date	May 5, 2006			
First Named Inventor	Shyam S. Mohapatra			
Group Art Unit	1635			
Examiner Name	Richard A. Schnizer			
Attorney Docket Number	USF.T193XC1			

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>			
	R1	CHHABRA, A. <i>et al.</i> "Silencing of Endogenous IL-10 in Human Dendritic Cells Leads to the Generation of an Improved CTL Response Against Human Melanoma Associated Antigenic Epitope, MART-1" <i>Clin Immunol.</i> , March 2008, 126(3):251-259.				
	R2	HEALE, B.S.E. <i>et al.</i> "siRNA target site secondary structure predictions using local stable substructures" <i>Nucleic Acids Research</i> , 2005, 33(3):e30, pp. 1-10.	1000			
	R3	HILL, J.A. et al. "Immune Modulation by Silencing IL-12 Production in Dendritic Cells Using Small Interfering RNA" <i>The Journal of Immunology</i> , 2003, 171:691-696.				
	R4	KRETSCHMER-KAZEMI, R. et al. "The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides" <i>Nucleic Acids Research</i> , 2003, 31(15):4417-4424.				
	R5	LI, M. et al. "Immune Modulation and Tolerance Induction by ReIB-Silenced Dendritic Cells through RNA Interference" The Journal of Immunology, 2007, 178:5480-5487.				
	R6	NAIR, M.P.N. et al. "RNAi-directed Inhibition of DC-SIGN by Dendritic Cells: Prospects for HIV-1 Therapy" <i>The AAPS Journal</i> , 2005, 7(3):E572-E578.				
	R7	NAWTAISONG, P. et al. "Effective suppression of Dengue fever virus in mosquito cell cultures using retroviral transduction of hammerhead ribozymes targeting the viral genome" <i>Virology Journal</i> , 2009, 6:73, pp. 1-17.				
	R8	QIAN, H. et al. "Silencing CD40 in Dendritic Cells by siRNA" 12 <sup>th</sup> International Congress of Immunology and 4 <sup>th</sup> Annual Conference of FOCIS, Montreal, Canada, July 18-23, 2004, 2004, pp. 339-348.				
	R9	SHAO, Y. et al. "Effect of target secondary structure on RNAi efficiency" RNA, 2007, 13:1631-1640.				
	R10	WESTERHOUT, E.M. et al. "A systematic analysis of the effect of target RNA structure on RNA interference" <i>Nucleic Acids Research</i> , 2007, 35(13):4322-4330.				
	R11	YOSHINARI, K. et al. "Effects on RNAi of the tight structure, sequence and position of the targeted region" Nucleic Acids Research, 2004, 32(2):691-699.				
	R12					
	R13					

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. Do NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.